依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床观察 点击下载
| 论文标题： | 依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：观察依达拉奉联合丁苯酞治疗急性缺血性脑卒中（AIS）的临床疗效及安全性。方法：选取AIS患者258例，按随机数字表法分为观察组和对照组，各129例。两组患者均给予抗血小板聚集、改善微循环、控制血压、降糖、调脂、稳定斑块和营养脑细胞等常规治疗。对照组患者在常规治疗基础上口服丁苯酞胶囊200 mg，tid；观察组患者在对照组基础上给予依达拉奉注射液30 mg加入氯化钠注射液100 ml中，ivgtt，bid。两组患者均持续治疗14 d。观察两组患者治疗前及治疗后7、14 d血清炎性因子、血清微小RNA（miR）222及神经功能缺损评分，并比较两组患者临床疗效及不良反应发生情况。 结果：治疗前，两组患者血清炎性因子、miR-222及神经功能缺损评分比较，差异均无统计学意义（P＞0.05）；治疗后7、14 d，两组患者血清炎性因子水平及神经功能缺损程度评分均显著降低，血清miR-222显著升高，且观察组明显优于对照组，差异均有统计学意义（P＜0.05）。观察组患者临床总有效率为92.2％，显著高于对照组的69.8％，差异有统计学意义（P＜0.05）。两组患者均未见明显不良反应发生。 结论：依达拉奉联合丁苯酞治疗AIS疗效显著，能明显降低患者血清炎性因子水平，促进miR-222表达，改善神经功能，且安全性较好。 |
| 英文摘要： | OBJECTIVE： To observe clinical efficacy and safety of edaravone combined with butyl phthalide in the treatment of acute ischemic stroke （AIS）. METHODS： 258 AIS patients were randomly divided into observation group and control group， with 129 cases in each group. Both groups were given routine treatment as antiplatelet， improving microcirculation， controlling blood pressure， lowering blood glucose， regulating blood lipid， keeping plaque stable， nourishing brain cells. Control group was additionally given Butyl phthalide capsules orally， 200 mg， tid. Observation group was additionally given Edaravone injection 30 mg added into Sodium chloride injection 100 ml， ivgtt， bid， on the basis of control group. Both groups continuously received 14 days of treatment. The serum inflammatory factor， miR-222 and neurologic impairment score of 2 groups were observed before treatment， 7， 14 d after treatment. Clinical efficacies and the occurrence of ADR were compared between 2 groups. RESULTS： There was no statistical significance in the serum inflammatory factor， miR-222 and neurologic impairment score between 2 groups before treatment （P＞0.05）. The serum inflammatory factor and neurologic impairment score of 2 groups were decreased significantly 7， 14 d after treatment， while serum levels of miR-222 were increased significantly； the observation group was significantly better than the control group， with statistical significance （P＜0.05）. Total effective rate of observation group was 92.2％， which was significantly higher than that of control group （69.8％）， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Edaravone combined with butyl phthalide is effective in the treatment of AIS， and can significantly decrease serum inflammatory factor level， promote the expression of miR-222 and improve neurologic function with good safety. |
| 期刊： | 2016年第27卷第29期 |
| 作者： | 伊恋，李星达，王建秀，张忠玲 |
| 英文作者： | YI Lian，LI Xingda，WANG Jianxiu，ZHANG Zhongling |
| 关键字： | 依达拉奉；丁苯酞；急性缺血性脑卒中；炎性因子；血清微小RNA222；神经功能 |
| KEYWORDS： | Edaravone； Butyl phthalide； Acute ischemic stroke； Inflammatory factor； miR-222； Neurologic function |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！